ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 803

Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis

Helin Masyan, Sinem Nihal Esatoglu, Ayse Merve Celik, Vedat Hamuryudan, Hasan Yazici and Emire Seyahi, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cardiovascular disease, comorbidity and rheumatic disease, Takayasu.s arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In addition to the occlusive vasculitis, hypertension and accelerated atherosclerosis are probably risk factors of the cardiovascular complications in Takayasu arteritis (TA). Although, management of traditional cardiovascular risk factors is recommended to diminish these cardiovascular complications, we still do not know whether traditional risk factors and other comorbid conditions are increased or operative. We looked at the frequency of traditional atherosclerotic risk factors and comorbid conditions among pts with TA.

Methods: Between March and December 2016, we studied consecutive 88 TA pts and 81 systemic lupus erythematosus (SLE) pts. In addition, 111 hospital workers were studied as healthy controls. Participants were interviewed with the help of a standardized questionnaire that assesses the presence of traditional atherosclerotic risk factors.  The presence of atherosclerosis was not separately assessed. The presence of comorbid conditions was also assessed with the help of the Charlson comorbidity index. Additionally, Framingham coronary heart disease risk score was calculated; however, this was done only for women, because there were only a few male patients in the study cohort and male gender is an independent risk factor in this calculation.  

Results: As shown in Table 1, among the Framingham components, only hypertension was significantly more frequent in TA. When only females were analyzed, Framingham risk score was more likely to be higher only in TA. Framingham score of SLE pts was found to be similar to that of the healthy controls, despite an increased frequency of hypertension observed among SLE pts. Additionally, familial history of cardiovascular diseases and sudden death were significantly more common among the TA pts compared to the SLE pts and healthy controls. Pericardial/pleural and renal diseases were more frequently observed among the SLE pts, (Table 2). On the other hand, cardiovascular and chronic pulmonary diseases were more common in TA pts. The frequency of inflammatory upper/lower back pain and rheumatologic diseases were increased in both TA and SLE. However, inflammatory bowel diseases (IBD) were only observed among the TA pts.

Conclusion: Among the traditional atherosclerotic risk factors, only hypertension appears to be increased among the TA pts. The frequencies of IBD and inflammatory upper/lower back pain are substantially high and deserves further scrutiny. Moreover, the increased incidence of cardiovascular and rheumatologic diseases among the first-degree relatives of TA pts suggest that genetic mechanisms may play role in TA.

 

Table 1. The demographic features and cardiovascular risk factors among females 

 

Takayasu arteritis

(n = 77)

SLE

(n =77)

Healthy controls

(n =87)

p value

Age, mean ± SD

44.5 ±12.6

42.5 ±12.4

44.6 ± 11.4

0.454

Smoking (current and past), n (%)

24 (31)

33 (45)

37 (42)

0.160

Body mass index, mean ± SD

26 ± 5

26 ± 6

26 ± 5

0.987

Total cholesterol, mg/dl

192 ± 47

186  ± 44

193 ± 36

0.580

HDL cholesterol, mg/dl

56 ± 14

59.5 ± 19

57 ± 15

0.470

Hypertension, n (%)

44 (57)

24 (31)

19 (22)

<0.0011

Diabetes mellitus, n (%)

7 (9)

8 (10)

12 (14)

0.612

Familial history of cardiovascular diseases, n (%)

36 (47)

16 (21)

22 (25)

0.0012

Familial history of sudden death,

n (%)

20 (26) ††

11 (14)

10 (11.5)

0.0363

Framingham risk score, median [IQR]

4.1 [1.8-9.4]

3.3 [1.3-5.8]

3.2 [1.1-5.9]

0.056

1TA–Healthy controls and SLE-Healthy controls, p <0.05; 2TA –SLE and TA-Healthy controls, p <0.05; 3 TA-SLE and TA-Healthy controls, p <0.05

 

Table 2. Comorbid diseases and accompanying rheumatologic diseases across the groups

 

Takayasu arteritis

(n = 88)

SLE

(n =81)

Healthy controls

(n=111)

p value

Female/male

77/11

77/4

87/24

0.00411

Age, mean ± SD

44.0 ±12.3

42.3±12.3

44.3 ± 11.7

0.482

Disease duration, median (IQR)

7 [3-12.8]

7 [4-14]

–

0.213

Chronic pulmonary diseases, n (%)

11 (12.5)

2 (2.5)

5 (4.5)

0.01722

Cardiovascular diseases, n (%)

38 (43.2)

18 (22.2)

10 (9.0)

<0.00133

Renal diseases, n (%)

12 (13.6)

21 (25.9)

8 (7.2)

0.00144

Neurologic diseases, n (%)

14 (15.9)

9 (11.1)

4 (3.6)

0.01255

Thyroid diseases, n (%)

12 (13.6)

20 (24.7)

24 (21.6)

0.172

Antidepressant drug use, n (%)

26 (29.5)

30 (37.0)

19 (17.1)

0.00766

Rheumatologic diseases

19 (21.6)

16 (19.8)

1

0.768

        Crohn’s disease/Ulcerative colitis

9 (10.2)

0

0

 

        Ankylosing spondylitis

3

0

0

 

        Behçet’s syndrome

3

0

0

 

        Takayasu’s arteritis

0

1

0

 

        Rheumatoid arthritis

1

2

0

 

        Psoriasis

3

3

1

 

        Anti-phospholipid syndrome

0

7

0

 

        Sjögren’s syndrome

0

3

0

 

Inflammatory upper/lower back pain

21 (23.9)

23 (28.4)

6 (5.4)

<0.0017

Pericarditis/pleuritis

7 (8.0)

13 (16.0)

0

0.0018

Family history of rheumatologic diseases

26 (29.5)

23 (28.4)

5 (4.5)

<0.0019

1: TA-Healthy controls and SLE-Healthy controls, p<0.05; 2 TA-SLE and TA-Healthy controls, p<0.05; 3 TA-Healthy controls and SLE-Healthy controls, p<0.05; 4 SLE-TA and SLE-Healthy controls, p<0.05; 5 TA-Healthy controls and SLE-Healthy controls, p<0.05; 6 TA-Healthy controls and SLE-Healthy controls, p<0.05;7 TA-Healthy controls and SLE-Healthy controls, p<0.05; 8 TA-Healthy controls and SLE-Healthy controls, p<0.05; 9 TA-Healthy controls and SLE-Healthy controls, p<0.05

 

 


Disclosure: H. Masyan, None; S. N. Esatoglu, None; A. M. Celik, None; V. Hamuryudan, None; H. Yazici, None; E. Seyahi, None.

To cite this abstract in AMA style:

Masyan H, Esatoglu SN, Celik AM, Hamuryudan V, Yazici H, Seyahi E. Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-risk-factors-and-comorbid-diseases-in-takayasus-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-factors-and-comorbid-diseases-in-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology